• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

替加环素联合头孢他啶-阿维巴坦治疗中性粒细胞减少症患者产 NDM-1 肺炎克雷伯菌菌血症:最后的治疗手段?

Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?

机构信息

Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Madero y Gonzalitos s/n, Colonia Mitras Centro, Monterrey, Nuevo León C.P. 64460, Mexico.

Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Madero y Gonzalitos s/n, Colonia Mitras Centro, Monterrey, Nuevo León C.P. 64460, Mexico.

出版信息

J Glob Antimicrob Resist. 2020 Dec;23:417-419. doi: 10.1016/j.jgar.2020.10.019. Epub 2020 Nov 16.

DOI:10.1016/j.jgar.2020.10.019
PMID:33212285
Abstract

OBJECTIVES

We report the successful treatment of a bloodstream infection caused by Klebsiella pneumoniae harbouring NDM-1 using aztreonam-ceftazidime-avibactam in a neutropenic patient in whom colistin and meropenem therapy had previously failed.

METHODS

A clinical isolate was evaluated to determine the presence of NDM, TEM, SHV, CTX, and CMY, and the killing kinetics of aztreonam (ATM; 4 μg/mL), aztreonam-avibactam (ATM-AVI; 4/4 μg/mL), and colistin (2 and 4 μg/mL) were tested.

RESULTS

ATM-AVI showed in vitro activity against the Klebsiella pneumoniae harbouring NDM-1, whereas colistin allowed re-growth.

CONCLUSIONS

This report supports reconsideration of use of colistin for treatment of infections caused by K. pneumoniae harbouring NDM. CZA/ATM use should be kept in mind as a treatment option, perhaps earlier than colistin.

摘要

目的

我们报告了一例中性粒细胞减少症患者成功治疗产 NDM-1 肺炎克雷伯菌血流感染的案例,该患者先前使用多黏菌素和美罗培南治疗无效,而使用氨曲南-头孢他啶-阿维巴坦治疗有效。

方法

评估临床分离株是否携带 NDM、TEM、SHV、CTX 和 CMY,并测试氨曲南(ATM;4μg/mL)、氨曲南-阿维巴坦(ATM-AVI;4/4μg/mL)和多黏菌素(2μg/mL 和 4μg/mL)的杀菌动力学。

结果

ATM-AVI 对产 NDM-1 肺炎克雷伯菌具有体外活性,而多黏菌素允许细菌重新生长。

结论

本报告支持重新考虑使用多黏菌素治疗产 NDM 肺炎克雷伯菌感染。在多黏菌素之前,应考虑使用 CZA/ATM 作为治疗选择。

相似文献

1
Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?替加环素联合头孢他啶-阿维巴坦治疗中性粒细胞减少症患者产 NDM-1 肺炎克雷伯菌菌血症:最后的治疗手段?
J Glob Antimicrob Resist. 2020 Dec;23:417-419. doi: 10.1016/j.jgar.2020.10.019. Epub 2020 Nov 16.
2
Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from study.头孢他啶/阿维巴坦联合氨曲南对产NDM和OXA-48样酶的微生物是否有效:研究所得经验教训
Indian J Med Microbiol. 2019 Jan-Mar;37(1):34-41. doi: 10.4103/ijmm.IJMM_19_189.
3
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
4
Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.监测头孢他啶-阿维巴坦和氨曲南在治疗一株携带肺炎克雷伯菌碳青霉烯酶 4 型和新德里金属β-内酰胺酶 1 型的多药耐药肠杆菌引起的血流感染中的浓度。
Clin Infect Dis. 2020 Aug 14;71(4):1095-1098. doi: 10.1093/cid/ciz1155.
5
Aztreonam, Ceftazidime/Avibactam, and Colistin Combination for the Management of Carbapenemase-Producing Bacteremia: A Case Report.替加环素、头孢他啶/阿维巴坦和多黏菌素联合治疗产碳青霉烯酶菌血症:病例报告。
J Pharm Pract. 2021 Aug;34(4):653-657. doi: 10.1177/0897190019882262. Epub 2019 Nov 7.
6
Detecting KPC-2 and NDM-1 Coexpression in Klebsiella pneumoniae Complex from Human and Animal Hosts in South America.检测南美人源和动物源肺炎克雷伯菌复合体中 KPC-2 和 NDM-1 的共表达。
Microbiol Spectr. 2022 Oct 26;10(5):e0115922. doi: 10.1128/spectrum.01159-22. Epub 2022 Aug 18.
7
Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.头孢他啶-阿维巴坦治疗持续中性粒细胞减少兔产碳青霉烯酶肺炎克雷伯菌肺炎的药代动力学和疗效。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02157-19.
8
Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.针对产 NDM-和 CTX-M 型肺炎克雷伯菌的细胞壁合成和外膜完整性的靶向治疗机制研究。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0052722. doi: 10.1128/aac.00527-22. Epub 2022 Aug 4.
9
Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland.波兰一家单中心对 23 例产新德里金属β-内酰胺酶(NDM)肺炎克雷伯菌感染患者使用头孢他啶/阿维巴坦和氨曲南治疗的结果。
Eur J Clin Microbiol Infect Dis. 2024 Aug;43(8):1579-1587. doi: 10.1007/s10096-024-04859-y. Epub 2024 May 29.
10
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性?
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.

引用本文的文献

1
Combatting mobile colistin-resistant (MCR), metallo-β-lactamase (MBL)-producing persisters.对抗耐黏菌素移动性(MCR)、产金属β-内酰胺酶(MBL)的持留菌。
JAC Antimicrob Resist. 2025 Jul 22;7(4):dlaf132. doi: 10.1093/jacamr/dlaf132. eCollection 2025 Aug.
2
Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland.波兰一家单中心对 23 例产新德里金属β-内酰胺酶(NDM)肺炎克雷伯菌感染患者使用头孢他啶/阿维巴坦和氨曲南治疗的结果。
Eur J Clin Microbiol Infect Dis. 2024 Aug;43(8):1579-1587. doi: 10.1007/s10096-024-04859-y. Epub 2024 May 29.
3
Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism against by MALDI-TOF MS.
通过基质辅助激光解吸电离飞行时间质谱法评估氨曲南和头孢他啶/阿维巴坦对……的协同作用
Antibiotics (Basel). 2023 Jun 16;12(6):1063. doi: 10.3390/antibiotics12061063.
4
Molecular Profiling of a Multi-Strain Hypervirulent Infection Within a Single Patient.一名患者体内多菌株高毒力感染的分子分析
Infect Drug Resist. 2023 Mar 11;16:1367-1380. doi: 10.2147/IDR.S404202. eCollection 2023.
5
Carbapenem-Resistant : Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options.耐碳青霉烯类:毒力因子、分子流行病学及治疗选择的最新进展
Antibiotics (Basel). 2023 Jan 21;12(2):234. doi: 10.3390/antibiotics12020234.
6
Current and Emerging Treatment Options for Multidrug Resistant Urosepsis: A Review.多重耐药性泌尿道感染的当前及新出现的治疗选择:综述
Antibiotics (Basel). 2022 Dec 15;11(12):1821. doi: 10.3390/antibiotics11121821.
7
Successful treatment of ceftazidime/avibactam combined with aztreonam in the NDM-producing Klebsiella pneumoniae bloodstream and intestinal infections in a NK/T lymphoma patient with agranulocytosis during autologous hematopoietic stem cell transplantation: a case report.头孢他啶/阿维巴坦联合氨曲南成功治疗1例自体造血干细胞移植期间粒细胞缺乏的NK/T淋巴瘤患者血流感染及肠道感染产NDM肺炎克雷伯菌:病例报告
Eur J Clin Microbiol Infect Dis. 2022 Nov 12:1-4. doi: 10.1007/s10096-022-04523-3.
8
The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases.氨曲南与阿维巴坦联合用于治疗产金属β-内酰胺酶革兰阴性菌的研究进展:体外研究与临床病例的系统评价
Antibiotics (Basel). 2021 Aug 20;10(8):1012. doi: 10.3390/antibiotics10081012.
9
An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by in Critically Ill Adult Patients.一种基于证据的多学科方法,专注于为重症成年患者中由[病原体名称未给出]引起的血流感染、复杂性尿路感染和复杂性腹腔内感染创建靶向治疗算法。
Infect Drug Resist. 2021 Jun 30;14:2461-2498. doi: 10.2147/IDR.S314241. eCollection 2021.